Glibenclamide Therapy in Type 2 Diabetes

DOI:

https://doi.org/10.37285/ijpsn.2009.2.1.11

Authors

  • Sai Laxmi M.
  • Venkatesham A.
  • A. Rama Narsimha Reddy
  • Shankaraiah P.
  • Krishna D. R.
  • Y. Narsihma Reddy

Abstract

Glibenclamide is a second generation sulfonylurea used in the treatment of type 2 diabetes. The study included 57 type 2 diabetic patients of either sex, aged above 21 years, an who were under treatment with glibenclamide. Blood samples were collected after 2 hours of drug intake and the next day, early morning before taking the drug. Serum glucose levels and glycosylated hemoglobin levels were estimated. The effect of glibenclamide treatment on long-term glycemic control was studied. There was no correlation between peak serum drug concentrations and post prandial glucose level as well as between trough serum drug and fasting glucose concentrations as could be observed from the coefficient of correlation (R2) values of 0.0319 and 0.0013, respectively. There is no correlation between peak serum drug concentration and HbA1c% as can be observed from the R2 value of 0.0101.The insignificant correlation between the parameters indicates that upon chronic therapy with glibenclamide desensitization and receptor down regulation occurs leading to loss of glycemic control. It was observed that the increased dose of glybenclamide also did not improve glycemic control.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Keywords:

Glibenclamide, blood glucose, glycosylated hemoglobin, type-2 diabetes

Downloads

Published

2009-05-31

How to Cite

1.
M. SL, A. V, Reddy ARN, P. S, D. R. K, Reddy YN. Glibenclamide Therapy in Type 2 Diabetes. Scopus Indexed [Internet]. 2009 May 31 [cited 2024 Dec. 23];2(1):465-70. Available from: https://ijpsnonline.com/index.php/ijpsn/article/view/325

Issue

Vol. 2 No. 1 (2009): April-June 2009

Section

Research Articles
Crossref
Scopus
Google Scholar
Europe PMC

References

Bunn H.F. Glycated hemoglobin. Diabetes. 30: 613-615 (1981).

DeFronzo RA, Bonadonna RC and Ferannini E. Pathogenesis of NIDDM: a balanced overview. Diabetes Care. 15: 318-368 (1992).

Ellis Se. Diabetes patient education: a meta analysis and meta regression. Patient Educ Couns. 52(1): 97-105 (2004).

Gary TL. Meta analysis of randomized educational and behavioral interventions in type 2 diabetes. Diab. Edu. 29(3): 488-501 (2003).

Geeta sharma DA. Prescribing trends of oral hypoglycemic agents in north India, their costs and impact on quality of life. Ind J Pharmacol. 35:128-136 (2003).

Hoffman A. The effect of hyperglycemia on the absorption of Diabetes Care in patients with NIDDM. Eur J Clin Pharmacol. 47(1): 53-65 (1994).

Jaber L. A. Comparison of pharmacokinetic and pharmacodynamics of short and long term glyburide therapy in NIDDM. Diabetes Care. 17(11): 1300-1306 (1994).

Jonsson A. Effects and serum levels of glibenclamide and its active metabolites in patients with type 2 diabetes. Diab. Ob. Metab. 3(60): 403-409 (2001).

Jonsson A. Slow elimination of glyburide in NIDDM subjects. Diabetes Care. 17(2): 142-145 (1994).

Karam JH. Selective unresponsiveness of pancreatic beta cells to acute sulfonylurea stimulation during sulfonylurea therapy in NIDDM. Diabetes. 35(12): 1314-1320 (1986).

Linda D and Janis W. Relationship between home glucose testing and hemoglobin HbA1c in type II diabetes patients. Am J Health-Syst Pharm. 54:1062-1065 (1997).

Martin S. Change in patients' body weight after 12 months of treatment with glimepiride or glibenclamide in Type 2 diabetes: a multi centre retrospective cohort study. Diabetologia. 46(12):1611-1617 (2003).

Mulder H. Extrapancreatic insulin effect of glibenclamide. Eur J Clin Pharmacol. 40(4):379-381 (1991).

Nieder M, Dilger C and Jaeger H. Determination of glibenclamide in human serum by HPLC. Journal of high resolution of chromatography. 9(2): 102-105 (2005).

Pearson JG. Pharmacokinetics of glyburide. Am J Med. 79 (3B): 67-71 (1985).

Peters AL and Davidson MB. Maximal dose glyburide therapy in markedly symptomatic patients with type 2 diabetes: a new use for an old friend.

J Clin Endocrinol Metab. 81(7): 2423-2427 (1996).

Prosser PR. The 24-hour effects of glyburide and chlorpropamide after chronic treatment of type II diabetic patients. Am J Med Sci. 289(5): 179-185 (1985).

Sartor G. Serum glibenclamide in diabetic patients and influence of food on the kinetics and effects of glibenclamide. Diabetologia. 18(1): 17-22 (1980).

Simcic KJ. Crossover comparison of maximum dose glyburide and glipizide. South Med J. 84(6): 743-746 (1991).

Singh T. The effect of sulphonylurea therapy on serum total cholesterol and high density lipoprotein cholesterol. J Indian Med Assoc. 90(10): 259-261 (1992).

Stenman S. What is the benefit of increasing the sulfonylurea dose? Diabetes Care. 118(3): 169-172 (1993).

Tankova T, Dakovsa G and Koev D. Education and quality of life in diabetic patients. Patient Educ Couns. 53(3): 285-290 (2004).

Trinder P. Guidelines on Standard Operating Procedures for clinical chemistry- glucose oxidase method. Ann. Clin. Biochem. (6): 24-27 (1969).

Trivelli LIA. Characterization of glucated hemoglobins. New Eng.J.Med . 284: 353-356 (1971)..

Wainscot J. Effects of glyburide treatment on serum lipoprotein and apolipoprotein concentrations and ratios in non-insulin-dependent diabetes mellitus. Clin Ther. 10(4): 392-400 (1988).

Yap WS. Review of management of type 2 diabetes mellitus. J Clin Pharm Ther. 23(6): 457-65 (1998).